NOTICE OF VIOLATION

Menorah Medical Center
Kansas City, Missouri

Docket No. 030-02295
030-00311
License No. 24-01239-01
24-01239-02

As a result of the inspection conducted on January 15, 1991, and in accordance with the "General Statement of Policy and Procedure for NRC Enforcement Actions," 10 CFR Part 2, Appendix C, (1989) (Enforcement Policy) the following violations were identified:

1. 10 CFR 35.59(g) requires, in part, that a licensee, in possession of a sealed source or a brachytherapy source, conduct a quarterly physical inventory of all such sources, retain those inventory records for five years and that the records contain the model number of each source and serial number, if one has been assigned, the identity of each source radionuclide and its nominal activity, the location of each source, and the signature of the Radiation Safety Officer.

   Contrary to the above, for the period of approximately March 1988 to March 1990, the licensee had not performed a physical inventory of its brachytherapy sources, an interval greater than one quarter.

   This is a Severity Level IV violation (Supplement VI).

2. 10 CFR 35.59(h) requires, in part, that a licensee in possession of a sealed source or brachytherapy source measure the ambient dose rates quarterly in all areas where such sources are stored.

   Contrary to the above, since approximately 1988, the licensee did not measure the ambient dose rates in the brachytherapy storage area where twelve cesium-137 sources were stored, a period exceeding one quarter.

   This is a Severity Level IV violation (Supplement VI).

3. 10 CFR 35.315(a)(4) requires that a licensee, promptly after administering a dosage of therapeutic radiopharmaceutical which requires hospitalization for compliance with 10 CFR 35.75, measure the dose rates in contiguous restricted and unrestricted areas with a radiation measurement survey instrument to demonstrate compliance with the requirements of 10 CFR Part 20.

   Contrary to the above, as of May 30, 1989, the licensee did not measure the dose rates in unrestricted areas, contiguous to a room of a patient who received 108 millicuries of iodine-131, a dosage which required hospitalization for compliance with 10 CFR 35.75.

   This is a Severity Level IV violation (Supplement VI).

Pursuant to the provisions of 10 CFR 2.201, you are required to submit to this office within thirty days of the date of this Notice a written statement or explanation in reply, including for each violation: (1) the corrective steps that have been taken and the results achieved; (2) the corrective steps that will be taken to avoid further violations; and (3) the date when full compliance will be achieved. Consideration may be given to extending your response time for good cause shown.

FEB 0 6 1991

Dated

Roy J. Caniano, Chief
Nuclear Materials Safety
Section 2